Recommendations of the Canadian Consensus Group on the Management of Chronic Myeloid Leukemia

Current Oncology

Volumn 13, Issue 6, 2006, Pages 201-221

  Laneuville, Pierre ^a,b   Barnett, M J ^c   Belanger R ^d   Couban, S ^e   Forrest, D L ^f   Roy, D C ^d   Lipton, J H ^g  

^a ROYAL VICTORIA HOSPITAL   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^d MAISONNEUVE ROSEMONT HOSPITAL   (Canada)

^e DALHOUSIE UNIVERSITY   (Canada)

^f VANCOUVER HOSPITAL AND HEALTH SCIENCES CENTRE   (Canada)

^g NONE

Author keywords

Chronic myeloid leukemia; Clinical practice guideline; Imatinib

Indexed keywords

ALPHA INTERFERON; BCR ABL PROTEIN; BUSULFAN; CYCLOPHOSPHAMIDE; CYTARABINE; HYDROXYUREA; IMATINIB;

ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; DIAGNOSTIC PROCEDURE; DISEASE MANAGEMENT; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE REGIMEN; DRUG RESISTANCE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EVIDENCE BASED MEDICINE; FLUID RETENTION; HUMAN; MEDICAL SOCIETY; MUSCLE CRAMP; PATHOGENESIS; PRACTICE GUIDELINE; PROGNOSIS; PROTEIN EXPRESSION; RASH; SIDE EFFECT; TREATMENT FAILURE; UNSPECIFIED SIDE EFFECT;

EID: 33845652307     PISSN: None     EISSN: 17187729     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Goldman JM, Melo JV. Chronic myeloid leukemia: advances in biology and new approaches to treatment. N Engl J Med 2003;349:1451-64.
2. Hehlmann R. Current CM therapy: progress and dilemma. Leukemia 2003;17:1010-12.
3. Schiffer CA, Hehlmann R, Larson R. Perspectives on the treatment of chronic phase and advanced phase CML and Philadelphia chromosome positive ALL. Leukemia 2003;17:691-99.
4. Sausville EA. Imatinib for chronic myelogenous leukaemia: a 9 or 24 carat gold standard. Lancet 2003;36:1400-1.
5. Druker BJ, O'Brien SG, Cortes J, Radich J. Chronic myelogenous leukemia. Hematology (Am Soc Hematol Educ Program) 2002:111-35.
6. Faderl S, Talpaz M, Estrov Z, O'Brien S, Kurzrock R, Kantarjian HM. The biology of chronic myeloid leukemia. New Engl J Med 1999;341:164-72.
7. Canadian Cancer Society and the National Cancer Institute of Canada. Canadian Cancer Statistics 2005. Toronto: Canadian Cancer Society; 2005.
8. Hill J, Meehan KR. Chronic myelogenous leukemia. Curable with early diagnosis and treatment. Postgrad Med 1999;106:149-59.
9. Cortez D, Stoica G, Pierce JH, Pendergast AM. The BCR-ABL tyrosine kinase inhibits apoptosis by activating a ras-dependent signaling pathway. Oncogene 1996;13:2589-94.
10. Salgia R, Brunkhorst B, Pisick E, et al. Increased tyrosine phosphorylation of focal adhesion proteins in myeloid cell lines expressing p210BCR/ABL. Oncogene 1995;11:1149-55.
11. Tauchi T, Boswell HS, Leibowitz D, Broxmeyer HE. Coupling between p210BCR-ABL and She and Grb2 adaptor proteins in hematopoietic cells permits growth factor receptor-independent link to ras activation pathway. J Exp Med 1994;179:167-75.
12. Salloukh HF, Laneuville P. Increase in mutant frequencies in mice expressing the BCR-ABL activated tyrosine kinase. Leukemia 2000;14:1401-4.
13. O'Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic phase chronic myeloid leukemia. N Engl J Med 2003;348:994-1004.
14. National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology. Chronic Myelogenous Leukemia. Version 2.2005 [online]. [Accessed at www.nccn.org/professionals/physician_gls/f_guidelines.asp; cited September 15, 2005]
15. Faderl S, Talpaz M, Estrov Z, Kantarjian HM. Chronic myelogenous leukemia: biology and therapy. Ann Intern Med 1999;131:207-19.
16. National Institute for Clinical Excellence. Guidance on the use of imatinib for chronic myeloid leukemia. Technology appraisal 70 [online]. London, U.K.: National Institute for Clinical Excellence; October 2003. [Accessed at www.nice.org.uk/page.aspx?o=89859; cited September 15, 2005]
17. Bernstein R. Cytogenetics of chronic myelogenous leukemia. Semin Hematol 1988;25:20-34.
18. Clarkson B, Strife A, Wisniewski D, Lambek CL, Liu C. Chronic myelogenous leukemia as a paradigm of early cancer and possible curative strategies. Leukemia 2003;17:1211-62.
19. Hasford J, Pfirrmann M, Hehlmann R, et al. A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group. J Nat Cancer Inst 1998;90:850-8.
20. Sokal JE, Cox EB, Baccarani M, et al. Prognostic discrimination in "good risk" chronic granulocytic leukemia. Blood 1984;63:789-99.
21. Marin D, Marktel S, Bua M, et al. Prognostic factors for patients with chronic myeloid leukemia in chronic phase treated with imatinib mesylate after failure of interferon alfa. Leukemia 2003;17:1448-53.
22. Huntly BJP, Bench A, Green AR. Double jeopardy from a single translocation: deletions of the derivative chromosome 9 in chronic myeloid leukemia. Blood 2003;102:1160-8.
23. Quintas-Cardama A, Kantarjian H, Talpaz M, et al. Deletion of derivative chromosome 9 has no prognostic impact on patients with chronic myeloid leukemia (CML) treated with imatinib mesylate (Gleevec) [abstract 640; online]. Blood 2003;102. [Accessed at www.bloodjournal.org/misc/ASH_Meeting_Abstracts_Info. shtml; cited October 30, 2006].
24. Cervantes F, on behalf of the IRIS Study Group. Durability of responses to imatinib in newly diagnosed chronic phase chronic myeloid leukemia: 24-month update from the IRIS study [abstract 633; online]. Blood 2003;102 [online]. [Accessed at www.bloodjournal.org/misc/ASH_Meeting_Abstracts_ Info.shtml; cited October 30, 2006].
25. Gratwohl A, Hermans J, Goldman J, et al. Risk assessment for patients with chronic myeloid leukemia before allogeneic blood or marrow transplantation. Lancet 1998;352:1087-92.
26. Radich JP, Gooley T, Bensinger W, et al. HLA-matched related hematopoietic cell transplantation for chronic phase CML using a targeted busulfan and cyclophosphamide preparative regi-men. Blood 2003;102:31-5.
27. Goldman JM, Marin D, Olavarria E, Apperley JF. Clinical decisions for chronic myeloid leukemia in the imatinib era. Semin Hematol 2003;40(suppl 2):98-103.
28. Bories D, Devergie A, Gardembas-Pain M, et al. Stratégies thérapeutiques et recommandations pour la prise en charge des patients atteints de leucémie myéloïde chronique. Hématologie 2003;9:497-512.
29. Walker I, Makarski J, Meyer RM, for the Hematology Disease Site Group. Treatment of chronic myeloid leukemia with imatinib. Practice guideline report #6-15 [online]. Toronto: Cancer Care Ontario; July 16, 2004. [Accessed at www.cancercare.on.ca/index_hematologyCancerguidelines.htm; cited September 16, 2005]
30. Druker BJ, Guilhot F, O'Brien S, Larson RA, on behalf of the IRIS Study Group. Long-term benefit of imatinib for patients newly diagnosed with chronic myeloid leukemia in chronic phase: 5-year update from the IRIS study [abstract 6506; online]. J Clin Oncol 2006;24(suppl). [Accessed at www.asco.org/portal/ site/asco/menuitem.34d60f5624ba07fd506fe310ee37a01d/?vgnextoid= 76f8201eb61a7010VgnVCM100000ed730ad1RCRD& vmview= abst_detail_view&confID=40&abstractID=32026; cited October 20, 2006]
31. Novartis Pharmaceuticals USA. The IRIS study: 5-year data [unpublished; data on file].
32. Baccarani M, Saglio G, Goldman J, et al. Evolving concepts in the management of chronic myeloid leukemia. Recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 2006;108:1809-20.
33. Druker BJ, Gathmann I, Bolton AE, et al., on behalf of the IRIS study group. Probability and impact of obtaining a cytogenetic response to imatinib as initial therapy for chronic myeloid leukemia in chronic phase [abstract 634; online]. Blood 2003;102. [Accessed at www.bloodjournal.org/misc/ ASH_Meeting_Abstracts_Info.shtml; cited October 30, 2006].
34. Radich JP, Gathmann I, Kaeda J, et al. Molecular response to imatinib and interferon plus Ara-C in newly diagnosed CML: efficacy of imatinib on patients after crossover from interferon therapy and prognostic importance of molecular response on long-term outcomes [abstract 635; online]. Blood 2003;102. [Accessed at www.bloodjournal.org/misc/ASH_Meeting_Abstracts_Info.shtml; cited October 30, 2006].
35. Silver RT, Woolf SH, Hehlmann R, et al. An evidence-based analysis of the effect of busulfan, hydroxyurea, interferon, and allogeneic bone marrow transplantation in treating the chronic phase of chronic myeloid leukemia: developed for the American Society of Hematology. Blood 1999;5:1517-36.
36. Novartis Pharmaceuticals Canada Inc. Gleevec [product monograph]. Rev. Dorval, QC: Novartis Pharmaceuticals Canada Inc.; June 16, 2006.
37. Cortes JE, Talpaz M, Giles F, et al. Prognostic significance of cytogenetic clonal evolution in patients with chronic myelogenous leukemia on imatinib mesylate therapy. Blood 2003;101:3794-3800.
38. Cortes JE, Talpaz M, O'Brien S, et al. High rates of major cytogenetic response in patients with newly diagnosed chronic myeloid leukemia in early chronic phase treated with imatinib at 400 mg or 800 mg daily [abstract 350; online]. Blood 2003;102. [Accessed at www.bloodjournal.org/misc/ ASH_Meeting_Abstracts_Info.shtml; cited October 30, 2006].
39. Kantarjian HM, Talpaz M, O'Brien S, et al. Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia. Blood 2003;101:473-5.
40. Kantarjian H, Talpaz M, O'Brien S, et al. High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia. Blood 2004;103:2873-8.
41. Cortes J, Talpaz M, O'Brien S, et al. High-dose imatinib mesylate treatment in patients with previously untreated early chronic phase chronic myeloid leukemia [abstract 999; online]. Blood 2004;104. [Accessed at www.abstracts2view.com/hem_sandiego2004/view.php?nu=HEM4L1_2741; cited September 15, 2005]
42. Gorre ME, Mohammed M, Ellwood K, et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001;293:876-80.
43. Shawver LK, Slamon D, Ullrich A. Smart drugs: tyrosine kinase inhibitors in cancer therapy. Cancer Cell 2002;1:117-25.
44. Branford S, Rudzki Z, Parkinson I, et al. Real-time quantitative PCR analysis can be used as a primary screen to identify patients with CML treated with imatinib who have BCR-ABL kinase domain mutations. Blood 2004;104:2926-32.
45. Branford S, Rudzki Z, Walsh S, et al. Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis. Blood 2003;102:276-83.